Portal de Periódicos da CAPES

Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata

2016; American Society for Clinical Investigation; Volume: 1; Issue: 15 Linguagem: Inglês

10.1172/jci.insight.89790

2379-3708

Julian Mackay‐Wiggan, Ali Jabbari, Nhan Nguyen, Jane Cerise, Charlotte Clark, Grace Ulerio, Megan Furniss, Roger Vaughan, Angela M. Christiano, Raphael Clynes,

Autoimmune Bullous Skin Diseases

BACKGROUND. Alopecia areata (AA) is a common autoimmune disease with a lifetime risk of 1.7%; there are no FDA-approved treatments for AA. We previously identified a dominant IFN-γ transcriptional signature in cytotoxic T lymphocytes (CTLs) in human and mouse AA skin and showed that treatment with JAK inhibitors induced durable hair regrowth in mice by targeting this pathway. Here, we investigated the use of the oral JAK1/2 inhibitor ruxolitinib in the treatment of patients with moderate-to-severe AA.